(IDXX) IDEXX Laboratories - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US45168D1046
Stock: Veterinary Analyzers, Water Tests, Lab Services, Software Platform
Total Rating 92
Risk 79
Buy Signal -0.56
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 34.2% |
| Relative Tail Risk | -19.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.15 |
| Alpha | 43.96 |
| Character TTM | |
|---|---|
| Beta | 0.985 |
| Beta Downside | 0.576 |
| Drawdowns 3y | |
|---|---|
| Max DD | 37.41% |
| CAGR/Max DD | 0.31 |
Description: IDXX IDEXX Laboratories January 29, 2026
IDEXX Laboratories (NASDAQ: IDXX) develops, manufactures, and distributes diagnostic and software solutions for companion-animal veterinary practices, water-quality testing, and livestock-poultry-dairy markets. The firm operates through three segments – Companion Animal Group, Water Quality Products, and Livestock, Poultry & Dairy – offering in-clinic analyzers, rapid SNAP test kits, cloud-based VetConnect PLUS, and a suite of reference-lab services.
Key recent metrics (Q4 2025 / FY 2025): revenue $4.02 billion, up 9 % YoY, driven by a 12 % increase in Companion Animal consumables and a 7 % rise in Water Quality product sales; operating margin expanded to 22.4 % as R&D efficiency improved; cash flow from operations reached $1.1 billion, supporting a $1.2 billion share-repurchase program. Sector drivers include a 5-year CAGR of ~6 % in U.S. pet-care spending, tightening EPA regulations that boost demand for rapid water-testing kits, and rising global protein demand that underpins livestock-diagnostic adoption.
For a deeper, data-driven comparison of IDXX’s valuation and risk profile relative to its peers, the ValueRay platform provides transparent analytics you can explore on your own.
Piotroski VR‑10 (Strict, 0-10) 9.0
| Net Income: 1.03b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.28 > 0.02 and ΔFCF/TA 4.50 > 1.0 |
| NWC/Revenue: 3.72% < 20% (prev 11.04%; Δ -7.32% < -1%) |
| CFO/TA 0.32 > 3% & CFO 1.09b > Net Income 1.03b |
| Net Debt (904.8m) to EBITDA (1.45b): 0.62 < 3 |
| Current Ratio: 1.12 > 1.5 & < 3 |
| Outstanding Shares: last quarter (80.7m) vs 12m ago -2.87% < -2% |
| Gross Margin: 61.72% > 18% (prev 0.61%; Δ 6111 % > 0.5%) |
| Asset Turnover: 123.7% > 50% (prev 114.7%; Δ 8.96% > 0%) |
| Interest Coverage Ratio: 35.32 > 6 (EBITDA TTM 1.45b / Interest Expense TTM 37.1m) |
Altman Z'' 10.00
| A: 0.05 (Total Current Assets 1.41b - Total Current Liabilities 1.25b) / Total Assets 3.39b |
| B: 1.81 (Retained Earnings 6.14b / Total Assets 3.39b) |
| C: 0.39 (EBIT TTM 1.31b / Avg Total Assets 3.37b) |
| D: 3.33 (Book Value of Equity 6.09b / Total Liabilities 1.83b) |
| Altman-Z'' Score: 12.33 = AAA |
Beneish M -2.88
| DSRI: 1.12 (Receivables 715.0m/587.1m, Revenue 4.17b/3.84b) |
| GMI: 0.98 (GM 61.72% / 60.76%) |
| AQI: 1.02 (AQ_t 0.33 / AQ_t-1 0.32) |
| SGI: 1.08 (Revenue 4.17b / 3.84b) |
| TATA: -0.02 (NI 1.03b - CFO 1.09b) / TA 3.39b) |
| Beneish M-Score: -2.88 (Cap -4..+1) = A |
What is the price of IDXX shares?
As of January 31, 2026, the stock is trading at USD 670.46 with a total of 762,043 shares traded.
Over the past week, the price has changed by -3.37%, over one month by -1.74%, over three months by +6.67% and over the past year by +58.13%.
Over the past week, the price has changed by -3.37%, over one month by -1.74%, over three months by +6.67% and over the past year by +58.13%.
Is IDXX a buy, sell or hold?
IDEXX Laboratories has received a consensus analysts rating of 3.62.
Therefor, it is recommend to hold IDXX.
- StrongBuy: 3
- Buy: 3
- Hold: 6
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the IDXX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 766 | 14.2% |
| Analysts Target Price | 766 | 14.2% |
| ValueRay Target Price | 743.8 | 10.9% |
IDXX Fundamental Data Overview January 29, 2026
P/E Trailing = 54.9644
P/E Forward = 48.5437
P/S = 13.3376
P/B = 35.535
P/EG = 4.1032
Revenue TTM = 4.17b USD
EBIT TTM = 1.31b USD
EBITDA TTM = 1.45b USD
Long Term Debt = 374.8m USD (from longTermDebt, last quarter)
Short Term Debt = 631.6m USD (from shortTermDebt, last quarter)
Debt = 1.11b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 904.8m USD (from netDebt column, last quarter)
Enterprise Value = 56.49b USD (55.58b + Debt 1.11b - CCE 208.2m)
Interest Coverage Ratio = 35.32 (Ebit TTM 1.31b / Interest Expense TTM 37.1m)
EV/FCF = 59.24x (Enterprise Value 56.49b / FCF TTM 953.6m)
FCF Yield = 1.69% (FCF TTM 953.6m / Enterprise Value 56.49b)
FCF Margin = 22.88% (FCF TTM 953.6m / Revenue TTM 4.17b)
Net Margin = 24.65% (Net Income TTM 1.03b / Revenue TTM 4.17b)
Gross Margin = 61.72% ((Revenue TTM 4.17b - Cost of Revenue TTM 1.60b) / Revenue TTM)
Gross Margin QoQ = 61.83% (prev 62.62%)
Tobins Q-Ratio = 16.68 (Enterprise Value 56.49b / Total Assets 3.39b)
Interest Expense / Debt = 0.96% (Interest Expense 10.7m / Debt 1.11b)
Taxrate = 20.35% (70.2m / 344.8m)
NOPAT = 1.04b (EBIT 1.31b * (1 - 20.35%))
Current Ratio = 1.12 (Total Current Assets 1.41b / Total Current Liabilities 1.25b)
Debt / Equity = 0.71 (Debt 1.11b / totalStockholderEquity, last quarter 1.56b)
Debt / EBITDA = 0.62 (Net Debt 904.8m / EBITDA 1.45b)
Debt / FCF = 0.95 (Net Debt 904.8m / FCF TTM 953.6m)
Total Stockholder Equity = 1.52b (last 4 quarters mean from totalStockholderEquity)
RoA = 30.50% (Net Income 1.03b / Total Assets 3.39b)
RoE = 67.78% (Net Income TTM 1.03b / Total Stockholder Equity 1.52b)
RoCE = 69.38% (EBIT 1.31b / Capital Employed (Equity 1.52b + L.T.Debt 374.8m))
RoIC = 41.98% (NOPAT 1.04b / Invested Capital 2.49b)
WACC = 9.37% (E(55.58b)/V(56.70b) * Re(9.54%) + D(1.11b)/V(56.70b) * Rd(0.96%) * (1-Tc(0.20)))
Discount Rate = 9.54% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.96%
[DCF Debug] Terminal Value 75.48% ; FCFF base≈889.2m ; Y1≈1.02b ; Y5≈1.43b
Fair Price DCF = 230.3 (EV 19.30b - Net Debt 904.8m = Equity 18.39b / Shares 79.9m; r=9.37% [WACC]; 5y FCF grow 17.61% → 2.90% )
EPS Correlation: 81.59 | EPS CAGR: 16.95% | SUE: 3.57 | # QB: 10
Revenue Correlation: 93.85 | Revenue CAGR: 8.96% | SUE: 2.02 | # QB: 2
EPS next Quarter (2026-03-31): EPS=3.42 | Chg30d=+0.009 | Revisions Net=-2 | Analysts=7
EPS next Year (2026-12-31): EPS=14.46 | Chg30d=+0.039 | Revisions Net=+1 | Growth EPS=+11.8% | Growth Revenue=+8.8%
P/E Forward = 48.5437
P/S = 13.3376
P/B = 35.535
P/EG = 4.1032
Revenue TTM = 4.17b USD
EBIT TTM = 1.31b USD
EBITDA TTM = 1.45b USD
Long Term Debt = 374.8m USD (from longTermDebt, last quarter)
Short Term Debt = 631.6m USD (from shortTermDebt, last quarter)
Debt = 1.11b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 904.8m USD (from netDebt column, last quarter)
Enterprise Value = 56.49b USD (55.58b + Debt 1.11b - CCE 208.2m)
Interest Coverage Ratio = 35.32 (Ebit TTM 1.31b / Interest Expense TTM 37.1m)
EV/FCF = 59.24x (Enterprise Value 56.49b / FCF TTM 953.6m)
FCF Yield = 1.69% (FCF TTM 953.6m / Enterprise Value 56.49b)
FCF Margin = 22.88% (FCF TTM 953.6m / Revenue TTM 4.17b)
Net Margin = 24.65% (Net Income TTM 1.03b / Revenue TTM 4.17b)
Gross Margin = 61.72% ((Revenue TTM 4.17b - Cost of Revenue TTM 1.60b) / Revenue TTM)
Gross Margin QoQ = 61.83% (prev 62.62%)
Tobins Q-Ratio = 16.68 (Enterprise Value 56.49b / Total Assets 3.39b)
Interest Expense / Debt = 0.96% (Interest Expense 10.7m / Debt 1.11b)
Taxrate = 20.35% (70.2m / 344.8m)
NOPAT = 1.04b (EBIT 1.31b * (1 - 20.35%))
Current Ratio = 1.12 (Total Current Assets 1.41b / Total Current Liabilities 1.25b)
Debt / Equity = 0.71 (Debt 1.11b / totalStockholderEquity, last quarter 1.56b)
Debt / EBITDA = 0.62 (Net Debt 904.8m / EBITDA 1.45b)
Debt / FCF = 0.95 (Net Debt 904.8m / FCF TTM 953.6m)
Total Stockholder Equity = 1.52b (last 4 quarters mean from totalStockholderEquity)
RoA = 30.50% (Net Income 1.03b / Total Assets 3.39b)
RoE = 67.78% (Net Income TTM 1.03b / Total Stockholder Equity 1.52b)
RoCE = 69.38% (EBIT 1.31b / Capital Employed (Equity 1.52b + L.T.Debt 374.8m))
RoIC = 41.98% (NOPAT 1.04b / Invested Capital 2.49b)
WACC = 9.37% (E(55.58b)/V(56.70b) * Re(9.54%) + D(1.11b)/V(56.70b) * Rd(0.96%) * (1-Tc(0.20)))
Discount Rate = 9.54% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.96%
[DCF Debug] Terminal Value 75.48% ; FCFF base≈889.2m ; Y1≈1.02b ; Y5≈1.43b
Fair Price DCF = 230.3 (EV 19.30b - Net Debt 904.8m = Equity 18.39b / Shares 79.9m; r=9.37% [WACC]; 5y FCF grow 17.61% → 2.90% )
EPS Correlation: 81.59 | EPS CAGR: 16.95% | SUE: 3.57 | # QB: 10
Revenue Correlation: 93.85 | Revenue CAGR: 8.96% | SUE: 2.02 | # QB: 2
EPS next Quarter (2026-03-31): EPS=3.42 | Chg30d=+0.009 | Revisions Net=-2 | Analysts=7
EPS next Year (2026-12-31): EPS=14.46 | Chg30d=+0.039 | Revisions Net=+1 | Growth EPS=+11.8% | Growth Revenue=+8.8%